FYREMADEL

This brand name is authorized in Finland, France, Malta, Netherlands, Poland, Spain, UK.

Active ingredients

The drug FYREMADEL contains one active pharmaceutical ingredient (API):

1	Ganirelix UNII 56U7906FQW - GANIRELIX ACETATE
	Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists.
	Read more about Ganirelix

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FYREMADEL Solution for injection in pre-filled syringe	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H01CC01	Ganirelix	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CC Anti-gonadotropin-releasing hormones
Discover more medicines within H01CC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	78205
FI	Lääkealan turvallisuus- ja kehittämiskeskus	409293, 551779
FR	Base de données publique des médicaments	61462270
GB	Medicines & Healthcare Products Regulatory Agency	349001, 349002
MT	Medicines Authority	AA770/16301
NL	Z-Index G-Standaard, PRK	59048
PL	Rejestru Produktów Leczniczych	100438472